This site is intended for healthcare professionals

FDA accepts NDA for mavacamten to treat symptomatic obstructive hypertrophic cardiomyopathy.- BMS

Read time: 1 mins
Last updated:20th Mar 2021
Published:20th Mar 2021
Condition: Hypertrophic Cardiomyopathy
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest